FT218: “72.0% of patients on FT218 compared to 31.6% of patients on placebo were rated as much or very much improved at Week 13; odds ratio 5.56 (p&lt;0.001)”; Sleep disorder

sodium oxybate ER (FT218) - Avadel

Apr 30, 2020